• Viking Therapeutics issued a correction to its Oct. 6, 2026 release on the VK2735 oral maintenance dosing trial.
• The earlier release incorrectly stated the study would evaluate weekly oral doses.
• The trial will evaluate maintenance options including daily oral doses, selected subcutaneous schedules, or placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610140705PR_NEWS_USPR_____LA71810) on October 14, 2026, and is solely responsible for the information contained therein.